Teladoc Inc
$ 7.78
3.32%
04 Dec - close price
- Market Cap 1,336,375,000 USD
- Current Price $ 7.78
- High / Low $ 7.81 / 7.33
- Stock P/E N/A
- Book Value 7.85
- EPS -1.26
- Next Earning Report 2026-02-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -0.15 %
- 52 Week High 15.21
- 52 Week Low 6.35
About
Teladoc Health, Inc. is a leading provider of comprehensive virtual healthcare services, operating both in the United States and internationally. Headquartered in Purchase, New York, the company leverages advanced telemedicine technology to deliver remote medical consultations, mental health support, and chronic disease management. With a commitment to improving accessibility and quality of care, Teladoc operates a vast network of medical professionals, making healthcare more convenient for millions of patients. As a pioneer in the telehealth sector, Teladoc is well-positioned to capitalize on the growing demand for innovative healthcare solutions in an increasingly digital world.
Analyst Target Price
$9.21
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-29 | 2025-07-29 | 2025-04-23 | 2025-02-18 | 2024-10-30 | 2024-07-31 | 2024-04-25 | 2024-02-20 | 2023-10-24 | 2023-07-25 | 2023-04-26 | 2023-02-22 |
| Reported EPS | -0.28 | -0.1473 | -0.2188 | -0.2451 | -0.19 | -0.28 | -0.49 | -0.17 | -0.35 | -0.4 | -0.42 | -23.49 |
| Estimated EPS | -0.2572 | -0.2632 | -0.358 | -0.2933 | -0.28 | -0.35 | -0.46 | -0.21 | -0.37 | -0.41 | -0.5 | -0.25 |
| Surprise | -0.0228 | 0.1159 | 0.1392 | 0.0482 | 0.09 | 0.07 | -0.03 | 0.04 | 0.02 | 0.01 | 0.08 | -23.24 |
| Surprise Percentage | -8.8647% | 44.035% | 38.8827% | 16.4337% | 32.1429% | 20% | -6.5217% | 19.0476% | 5.4054% | 2.439% | 16% | -9296% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.1814 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TDOC
2025-11-02 15:46:26
Teladoc Health reported a significant net loss of $13.7 billion for 2022, largely attributed to a write-off related to its 2020 acquisition of Livongo. This substantial loss, following an $18.5 billion acquisition, has raised concerns about the pace of digital health adoption and suggests a potential slowdown in industry funding. Despite these challenges, Teladoc's CEO expressed optimism about future growth and an increased focus on efficiency, while others in the industry note a cooling in digital health investments.
2025-10-18 00:28:55
Teladoc (TDOC) stock dropped -5.43% while the broader market gained. Despite the recent dip, Teladoc's stock has seen a 9.2% increase over the past month, outperforming the Medical sector and the S&P 500. The company is set to announce its earnings on October 29, 2025, with anticipated EPS of -$0.26 and revenue of $625.2 million.
2025-10-18 00:28:55
Teladoc (TDOC) stock closed down 5.43% at $8.53, while the broader market saw gains. Despite this daily dip, TDOC has outperformed its sector and the S&P 500 over the past month. Investors are anticipating its Q4 2025 earnings report, with Zacks analysts expecting a significant EPS increase for the full year and currently rating the stock as a #2 (Buy).
2025-10-17 17:22:00
TELADOC HEALTH INC. disclosed $190,000 in lobbying expenditures for Q3 2025, focusing on the "CONNECT for Health Act of 2025." The article also details recent insider sales totaling over $600,000, hedge fund activity with significant buys and sells, and analyst ratings and price targets for TDOC stock.
2025-10-17 10:54:23
This article compares Iovance Biotherapeutics and Teladoc Health, two healthcare stocks that have significantly underperformed the market. It delves into the investment case for each company, highlighting their respective challenges and potential for a comeback. Ultimately, the article suggests Teladoc Health as the marginally more attractive option for contrarian investors with a high-risk tolerance due to its higher revenue, lower net losses, and established industry presence.
2025-10-17 10:17:52
This article compares Iovance Biotherapeutics and Teladoc Health, two healthcare companies with beaten-down stocks, to determine which is a more attractive contrarian buy. While both face significant challenges and are considered risky, the analysis concludes that Teladoc Health is the better option due to its higher revenue, lower net losses, and established industry presence.
